Macrogen

MacroGenics to Participate in Upcoming Investor Conferences

Retrieved on: 
Giovedì, Marzo 3, 2022
Macrogen, Biotechnology, Company, Cancer, Conference, Protein engineering, Investor relations, Nasdaq, GLOBE, Therapy, Pharmaceutical industry, MD

MacroGenics President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate on the Gastrointestinal/Genitourinary Oncology Panel, Tuesday, March 8, 2022, at 10:30 am ET.

Key Points: 
  • MacroGenics President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate on the Gastrointestinal/Genitourinary Oncology Panel, Tuesday, March 8, 2022, at 10:30 am ET.
  • MacroGenics management is scheduled to participate in a fireside chat and provide a corporate overview on Tuesday, March 15, 2022, at 3:50 pm ET.
  • Webcasts of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm .
  • MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

MacroGenics Announces Executive Promotion

Retrieved on: 
Lunedì, Febbraio 28, 2022
GLOBE, Judgement, Therapy, Securities Exchange Act of 1934, Negotiation, Stanford University, Security (finance), NASDAQ, Company, Yale University, Johnson & Johnson, U.S. Securities and Exchange Commission, Macrogen, Protein engineering, Senior, Biotechnology, Leadership, Business development, Securities Act of 1933, Cancer, Patient, Program, Fine chemical, Management, Pharmaceutical industry, MD

Prior to joining MacroGenics, Mr. Risser held the position of Senior Director, Business Development in the pharmaceutical group at Johnson & Johnson, where he worked from 2003 to 2009.

Key Points: 
  • Prior to joining MacroGenics, Mr. Risser held the position of Senior Director, Business Development in the pharmaceutical group at Johnson & Johnson, where he worked from 2003 to 2009.
  • "Eric has been an effective and strategic leader within MacroGenics.
  • The creation of this new position reflects our confidence in his judgment, ability and leadership to more efficiently advance our product candidates and create value for our shareholders," said Scott Koenig, M.D., Ph.D., President and Chief Executive Officer of MacroGenics.
  • MacroGenics (the Company) is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer.

MacroGenics Announces Date of Fourth Quarter 2021 Financial Results Conference Call

Retrieved on: 
Lunedì, Febbraio 14, 2022
Webcast, Cancer, Protein engineering, Company, Nasdaq, Therapy, Macrogen, Biotechnology, Conference, Investor relations, GLOBE, Pharmaceutical industry, MD

MacroGenicswill host a conference call to discuss the financial results and recent corporate progress onThursday, February 24, 2022,at4:30 pm ET.

Key Points: 
  • MacroGenicswill host a conference call to discuss the financial results and recent corporate progress onThursday, February 24, 2022,at4:30 pm ET.
  • The conference call can be accessed by dialing (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and providing the Conference ID# 1067087.
  • The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at http://ir.macrogenics.com/events.cfm .
  • MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

MacroGenics to Participate in Upcoming Investor Conferences

Retrieved on: 
Giovedì, Febbraio 3, 2022
GLOBE, Investor relations, Macrogen, Therapy, Protein engineering, Company, Biotechnology, Conference, Nasdaq, Cancer, Fine chemical, Medical device, MD

MacroGenics management will participate in a fireside chat on Thursday, February 10, 2022, at 9:00 am ET.

Key Points: 
  • MacroGenics management will participate in a fireside chat on Thursday, February 10, 2022, at 9:00 am ET.
  • MacroGenics management will participate in a fireside chat on Thursday, February 17, 2022, at 12:30 pm ET.
  • MacroGenics management will participate in a fireside chat on Friday, February 18, 2022, at 10:40 am ET.
  • MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

Synaffix Inks Deal with MacroGenics to Enable Next Generation ADCs

Retrieved on: 
Giovedì, Febbraio 3, 2022
Macrogen, Therapy, ADC, Moa, Aravis, Biotechnology, Therapeutic index, Technology, Research, DART, Kyowa Hakko Kirin, Cancer, Program, Nasdaq, Control, Fine chemical, Pharmaceutical industry, Synaffix

These will be combined with MacroGenics' proprietary antibody and bispecific DART antibody platform technologies to generate next generation ADCs.

Key Points: 
  • These will be combined with MacroGenics' proprietary antibody and bispecific DART antibody platform technologies to generate next generation ADCs.
  • MacroGenics will be responsible for research, development, manufacturing and commercialization of the ADCs.
  • Ezio Bonvini, M.D., Chief Scientific Officer of MacroGenics, commented:"We are delighted to be working with Synaffix to produce next generation ADCs with potentially superior therapeutic properties.
  • Peter van de Sande, Chief Executive Officer of Synaffix, said:"The collaboration with MacroGenics is an important milestone for Synaffix as our ADC technology will be deployed for the generation of both monospecific and bispecific ADCs.

Synaffix Inks Deal with MacroGenics to Enable Next Generation ADCs

Retrieved on: 
Giovedì, Febbraio 3, 2022
Macrogen, Therapy, ADC, Moa, Aravis, Biotechnology, Therapeutic index, Technology, Research, DART, Kyowa Hakko Kirin, Cancer, Program, Total, Nasdaq, Control, Fine chemical, Pharmaceutical industry, Synaffix

AMSTERDAM, Feb. 3, 2022 /PRNewswire/ -- Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces it has entered into a technology agreement with MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer.

Key Points: 
  • These will be combined with MacroGenics' proprietary antibody and bispecific DART antibody platform technologies to generate next generation ADCs.
  • MacroGenics will be responsible for research, development, manufacturing and commercialization of the ADCs.
  • Ezio Bonvini, M.D., Chief Scientific Officer of MacroGenics, commented:"We are delighted to be working with Synaffix to produce next generation ADCs with potentially superior therapeutic properties.
  • Peter van de Sande, Chief Executive Officer of Synaffix, said:"The collaboration with MacroGenics is an important milestone for Synaffix as our ADC technology will be deployed for the generation of both monospecific and bispecific ADCs.

Checkmate Pharmaceuticals Welcomes Industry Leader Jon Wigginton, M.D. to its Board of Directors

Retrieved on: 
Lunedì, Gennaio 31, 2022
Immune system, University, Twitter, Securities Act of 1933, Board of directors, TLR9, COVID-19, CpG, File, B.S, GLOBE, Biology, Senior advisor, U.S. Securities and Exchange Commission, Review, Immunotherapy, Financial condition report, Society, Interim, Merck & Co., Analysis, Drug development, Security (finance), Society for Immunotherapy of Cancer, Leadership, Government, NASDAQ, National, Discovery, Result, Wigginton, Private Securities Litigation Reform Act, Bristol Myers Squibb, Clinical Oncology, BMS, Group medical practice in the United States, Forward-looking statement, Patient, Center, National Cancer Institute, SITC, Social media, Board, Lymphatic system, Annual report, SAB, Macrogen, LinkedIn, Director, Fine chemical, Pharmaceutical industry, Checkmate

to its Board of Directors (Board).

Key Points: 
  • to its Board of Directors (Board).
  • With his diverse background, he has driven numerous clinical stage immuno-oncology development portfolios, said Alan Fuhrman, Interim CEO and President of Checkmate.
  • Prior, he was Chief Medical Officer at MacroGenics, where he led the companys evolution of a fully-integrated clinical-stage cancer immunotherapy organization.
  • The information that Checkmate Pharmaceuticals posts on these channels and websites could be deemed to be material information.

Global LAG 3 Inhibitor Market Opportunity & Clinical Trials Insight Report 2022-2028 - ResearchAndMarkets.com

Retrieved on: 
Lunedì, Gennaio 31, 2022
Health, Clinical Trials, NK, Infection, Immunoglobulin superfamily, Patient, TIL, Therapy, Cell, PD-1, Diabetes, Non-Hodgkin lymphoma, Lung, Nivolumab, Cancer, IMP321, Stomach, Ono Pharmaceutical, Multiple myeloma, Immunotherapy, Adoption, US, Degenerative disease, Cell cycle, HIV, Hope, Neoplasm, Company, TILS, PD-L1, Melanoma, Bristol Myers Squibb, Leukemia, Monoclonal antibody, Merck, Histocompatibility, US FDA, Apoptosis, Novartis, Breast cancer, Macrogen, Immutep, Lymphoma, Multiple sclerosis, B cell, Antibody, Relatlimab, Autoimmunity, LAG3, Pharmaceutical industry, Vaccine

The "Global LAG 3 Inhibitor Clinical Trials & Market Opportunity Insight 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global LAG 3 Inhibitor Clinical Trials & Market Opportunity Insight 2028" report has been added to ResearchAndMarkets.com's offering.
  • The key players in the market include MacroGenics, Zai Lab, Bristol-Myers Squibb, Ono Pharmaceuticals, Immutep, Novartis, Merck, F-star Therapeutics, among others.
  • Cancer immunotherapy is a novel approach which can reverse tumor immune escape by suppressing immune checkpoint pathways.
  • Global LAG 3 Inhibitor Clinical Trials & Market Opportunity Insight 2028 Report Highlights:
    LAG 3 Inhibitors Trials By Phase, Company, Country, Indication

DGAP-News: BB BIOTECH AG: 2021 was a difficult year for biotech equity markets - increased dividend of CHF 3.85 proposed

Retrieved on: 
Venerdì, Gennaio 21, 2022
Net asset value, Vaccination, Technology, Patient, Vertex, Annual report, Vaccine, Biotechnology, Clinical trial, Bipolar disorder, Swings, RNA, AGM, COVID-19, Board of directors, Severe acute respiratory syndrome coronavirus 2, Blas, Policy, EUA, CEO, NBI, Nasdaq Composite, Industry, BB Biotech, Government, Annual, Executive, Beta thalassemia, Destiny, CRISPR Therapeutics, Therapy, Prognosis, Macrogen, Gene editing, GMG, Environment, SPI, NDAS, Director, NAV, Dow Jones, Blood, FDA, CRISPR, Conditional sentence, Omicron, Annual general meeting, Board, Investment, Fine chemical, Pharmaceutical industry, Bank, Alnylam Pharmaceuticals, Ionis, EUR, CHF, Neurocrine, USD

Media release as at January 21, 2022

Key Points: 
  • Media release as at January 21, 2022
    Portfolio of BB Biotech AG as at December 31, 2021
    The year 2021 was a volatile market environment for all involved in biotechnology investing, including BB Biotech.
  • BB Biotech carefully adjusted the portfolio in the last three months of 2021.
  • The net loss for BB Biotech in 2021 was CHF 405 mn.
  • The highly specialized investment team at BB Biotech believes that the growth case for biotechnology and valuations for portfolio companies are both compelling.

Psomagen, Inc. Makes Key Tools and Technologies Accessible and Scalable Through Partnerships With 10x Genomics and Olink Proteomics

Retrieved on: 
Giovedì, Gennaio 20, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Epigenomics, Genomics, RNA, Proteomics, SCS, CLIA, Gene, CEO, Disease, Solution, DNA, Industry, Macrogen, Environment, Gene expression, Biomedical Research, Metagenomics, Behavior, Drug discovery, CSP, Vaccine

Were committed to bridging the gap between biomedical research and individualized healthcare, said Ryan Kim , CEO at Psomagen.

Key Points: 
  • Were committed to bridging the gap between biomedical research and individualized healthcare, said Ryan Kim , CEO at Psomagen.
  • Additionally, the company offers Olink Proteomics Explore 1536 & 3072 Platform, Target 96 Panels, Target 48 Cytokine, and Focus 21 Custom Panels.
  • Learn more about Psomagens US-based CLIA-certified and CAP-accredited facilities, and genomics , epigenomics , transcriptomics , and proteomics offerings at www.psomagen.com .
  • The company makes cutting-edge genomics, epigenomics, metagenomics, transcriptomics, and proteomics technologies accessible to the clinical and academic markets.